Industry Collaborators

Merck Logo


OncoSec Medical Inc. entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of OncoSec’s ImmunoPulse® IL-12 and  Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a phase 2b clinical trial, referred to as PISCES/KEYNOTE-695. Read the Press Release »

Real Time Web Analytics